Completed PHASE1 INTERVENTIONAL 2-arm
NCT06902090
Safety, Tolerability and Pharmacokinetics of Meloxicam Nanocrystal Injection in Healthy Subjects
Sponsor: Yangtze River Pharmaceutical Group Co., Ltd.
Conditions
Pain
Interventions
Meloxicam Nanocrystal Injection (ANJESO®) Meloxicam Nanocrystal Injection(Yangtze River Pharmaceutical Group Co., Ltd.)
Updated 1 time since 2025 Last updated: Mar 24, 2025 Started: Jul 5, 2023 Primary completion: Jul 25, 2023 Completion: Aug 25, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT06902090, this PHASE1 trial focuses on Pain and remains completed. Sponsored by Yangtze River Pharmaceutical Group Co., Ltd., it has been updated 1 time since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
1 version recorded Completed — PHASE1
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Yangtze River Pharmaceutical Group Co., Ltd.
Data source: Yangtze River Pharmaceutical Group Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .